SGCB and diabetic kidney disease: For instance, avenciguat (synonym: BI568809), as an sGC activator, demonstrates significant advantages in treating metabolic diseases such as DKD, obesity-related disorders, and cardiovascular complications, particularly under oxidative stress, where its efficacy may surpass that of sGC stimulators [25].